## **PRKAR1B** Antibody

PACO18829




## **Product Information** Size: **Protein Background:** 50ul Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to **Reactivity:** factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-Human, Mouse, Rat kininogen shows a variety of physiological effects: (4A) influence in smooth muscle Source: contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in Rabbit vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via **Isotype:** bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMWlgG kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. **Applications:** Gene ID: ELISA, IHC PRKAR1B **Recommended dilutions:** Uniprot ELISA:1:2000-1:10000, IHC:1:50-1:200 P31321 Synonyms: Protein kinase, cAMP-dependent, regulatory, type I, beta Immunogen:

Synthetic peptide of human PRKAR1B.

## Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol



The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using PACO18829(PRKAR1B Antibody) at dilution 1/60, on the right is treated with synthetic peptide. (Original magnification: x—200).

The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using PACO18829(PRKAR1B Antibody) at dilution 1/60, on the right is treated with synthetic peptide. (Original magnification: x—200).